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ABSTRACT
Although marrow adipocytes and osteoblasts derive from a common bone marrow stromal cells (BMSCs), the mechanisms that underlie
osteoporosis-associated bone loss andmarrow adipogenesis during prolonged steroid treatment are unclear. We show in human BMSCs
(hBMSCs) that glucocorticoid receptor (GR) signaling in response to high concentrations of glucocorticoid (GC) supports adipogenesis
but inhibits osteogenesis by reducing c-Jun expression and hBMSC proliferation. Conversely, significantly lower concentrations of GC,
which permit hBMSC proliferation, are necessary for normal bone mineralization. In contrast, platelet-derived growth factor (PDGF)
signaling increases both JNK/c-Jun activity and hBMSC expansion, favoring osteogenic differentiation instead of adipogenesis. Indeed,
PDGF antagonizes the proadipogenic qualities of GC/GR signaling. Thus our results reveal a novel c-Jun-centered regulatory network of
signaling pathways in differentiating hBMSCs that controls the proliferation-dependent balance between osteogenesis and adipogen-
esis.  2010 American Society for Bone and Mineral Research.
KEY WORDS: OSTEOBLASTS AND STEM CELLS; BONE; ADIPOSE; CORTICOSTEROID OSTEOPOROSIS
Introduction
Several types of cells constitute bone: osteoblasts (bone-forming cells), osteoclasts (bone-reabsorbing cells) and
osteocytes, which are mature osteoblasts that become trapped
and surrounded by self-generated bone matrix. Bone tissue is
constantly reabsorbed by osteoclasts and replaced by osteo-
blasts, a process known as bone remodeling that is under
paracrine control to maintain bone integrity in healthy
individuals. It is believed that precursors of osteoclasts share
properties with the monocyte-macrophage cell lineage, suggest-
ing a hematopoietic origin.(1) Conversely, osteoblasts, and
therefore osteocytes, descend from bone marrow stromal cell
lineages (BMSCs). BMSCs serve as precursors for various
mesodermal tissues, including cartilage, adipose, connective,
and the aforementioned osseous tissues.(2,3)
Osteoporosis is a debilitating condition characterized by low
bone mass and increased bone fragility. This loss of bone
appears to coincide with declining numbers of osteoblasts and a
concomitant increase in adipocytes.(4) Indeed, an increase in
marrow adipocytes is observed in all conditions that lead to
bone loss, such as aging,(5) immobilization,(6) microgravity,(7)
ovariectomy,(8) anorexia nervosa,(9) and treatment with gluco-
coticoids.(10,11) Although the pathogenesis of osteoporosis is
multifactorial, these observations suggest that differentiation of
BMSCs into adipocytes at the expense of osteoblasts is a major
mechanism underlying osteoporotic disease.
The administration of steroid hormones such as glucocorti-
coids (GCs) is an effective and much-used anti-inflammatory
therapy for several serious chronic diseases (eg, asthma and
rheumatoid arthritis) and for preventing transplant rejection.
GCs interact with the cognate intracellular glucocorticoid
receptor (GR), which belongs to the nuclear receptor superfamily
and regulates the transcription of a range of target genes.
Hormone binding induces GR activation and translocation to the
nucleus,(12) where the hormone-receptor complex recognizes
specific DNA sequences known as glucocorticoid response
elements (GREs).(13) In addition, GR also can modulate the
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expression of genes through a GRE-independent mechanism,
such as protein-protein interaction of GR with other regulatory
factors. Indeed, the main immunosuppressive and anti-inflam-
matory actions of GCs are mediated by trans-repression of the
transcription factors AP-1 and nuclear factor-kB (NF-kB), which
are known to regulate many genes involved in the immune
response.(14–16)
Despite their considerable efficacy as anti-inflammatory
agents, severe side effects frequently limit GC use. Among
these is the development of osteoporosis,(17) in which prolonged
GC administration correlates with extended osteoclast life span,
decreased osteoblast precursor proliferation and terminal
differentiation, and increased apoptosis of both osteoblasts
and mature osteocytes. Thus therapeutically administered GCs
simultaneously reduce bone formation while enhancing reab-
sorption of bone tissue, generating an imbalance in the
remodeling process that weakens the bone significantly.
Somewhat at odds with these observations in vivo, GCs
are required in vitro for standard protocols of hBMSC
differentiation to both osteoblasts and adipocytes. The work
presented here investigates this apparent paradox, focusing on
the molecular signals that regulate hBMSC proliferation with
respect to osteogenesis and adipogenesis. We demonstrate that
high concentrations of GC permit adipogenesis but impair
osteogenesis by inhibiting proliferation and c-Jun expression. In
contrast, the growth factor platelet-derived growth factor (PDGF)
increases c-Jun activity and antagonizes the proadipogenic
effects of GC administration. Thus the characterisation of this
c-Jun-centered regulatory network provides insight on the
differential response of hBMSCs to GCs that underpins the shift
from osteogenesis to adipogenesis associated with GC-induced
osteoporosis.
Materials and Methods
Culture and differentiation of hBMSCs
Human bone marrow–derived BMSCs (hBMSCs) were obtained
from Inbiobank Stem Cell Bank (www.inbiobank.org). Cadaveric
bone marrow was harvested from brain-dead donors after
informed consent and under the Spanish National Organization
of Transplant [Organizacio´n Nacional de Transplantes (ONT)]
supervision. Each donor sample was tested and found negative
for HIV-1/2, hepatitis B and C, cytomegalovirus, andMycoplasma.
All cells were processed at Inbiobank following manufacturing
procedures based on ISO9001:2000 under good manufacturing
practices (GMPs). Generated hBMSCs display a typical CD13þ,
CD29þ, CD73þ, CD90þ, CD105þ, CD166þ, CD146þ, CD34–, CD45–,
CD14–, CD19–, and CD31– phenotype; a fibroblast-like morphol-
ogy; and at least trilineage potential, including osteocyte,
chondrocyte, and adipocyte generation (Supplemental Fig. 1).
hBMSCs were cultured in low-glucose DMEM (Sigma, www.sig-
maaldrich.com) supplemented with 10% FBS preselected for
BMSC optimal growth. On reaching confluence, hBMSCs were
trypsinized and seeded at a density of 1 103 cells/cm2 to
expand cell culture constituting a passage. Cells were obtained in
passage number 3 from the Stem Cell Bank. All experiments were
carried out with cultures of low passage (passages 4 to 7).
Included in the adipogenic medium weere 1 mM dexametha-
sone, 500 mM 2-isobutyl-1-methylxantine (IBMX), and 200 mM
indomethacin (Sigma). Included in the osteogenic medium were
50 mM ascorbic acid, 10mM b-glycerophosphate, and 0.1 mM
dexamethasone (Sigma). For osteogenic visualization, cells were
fixed using 70% ethanol and stained in alizarin red S 2% for
10minutes. Stained cells were washed twice with distilled water.
For quantification of staining, the monolayer was transferred
with 10% acetic acid, heated to 858C for 10 minutes, and
transferred to ice for additional 5 minutes. Ammonium
hydroxide was added to neutralize the acid. Samples were read
at 405 nm in an Ultrospec 2000 spectrophotometer. SP600125,
RU-486 (Mifepristone), and PDGF-BB were purchased from Sigma
and used at the corresponding concentrations.
shRNA- and cDNA-transduced cells
shRNA and cDNA vectors were constructed by using standard
cloning procedures. c-Jun and GR shRNA oligonucleotides were
purchased from Sigma-Genosys (www.sigmaaldrich.com): c-Jun
(Accession No. NM_002228, sequence 1553–1573)(18) and
glucocorticoid receptor (Accession No. NM_000176, sequence
2086–2114; www.origene.com). Oligonucleotides were annealed
and cloned into the pSUPER plasmid carrying the Pol III–
dependent H1 promoter. The H1-shRNA expression cassette
then was excised and cloned into the lentiviral pLVTHM plasmid
using EcoRI-ClaI sites (Addgene Plasmid 12247, www.addgen-
e.org).(19) c-Jun cDNA was purchased from imaGenes (Clone
IRATp970B0488D6, www.imagenes-bio.de), related to the NCBI
c-Jun sequence NM_000228. c-Jun cDNAwas excised and cloned
into the pSP72 vector (Promega Plasmid P2191, www.prome-
ga.com) using EcoRI and BamH1. EcoRV and PvuII were used to
get c-Jun cDNA from pSP72, and it was cloned in the PmeI
cassette of pWPI plasmid (Addgene Plasmid 12254). c-Jun cDNA
as well as GR and c-Jun shRNA sequences were checked after
cloning in pWPI and pLVTHM vectors to confirm 100%
correspondence with the original sequences. Viral particles
were produced in human embryonic kidney 293T cells (ATCC,
www.atcc.org). Briefly, 293T cells were seeded in high-glucose
DMEM containing 10% FBS. pRRE, pREV, pVSV-G, and the
lentiviral vector pLVTHM or pWPI containing both the GFP
reporter gene and the shRNA or cDNA sequences were
transfected in the packaging cell line by calcium phosphate
precipitation in the presence of 25 mM chloroquine (Sigma).
Transductions were carried out at various multiplicity of
infections (MOIs) in the presence of 8 mg/mL of polybrene
(Sigma). In order to achieve 100% infection, MOIs 9 and10 were
used (for osteogenic differentiation assay and Western blot). To
achieve 50% infection, MOIs 3 and 4 were used (for adipogenic
differentiation and proliferation assays).
Expression analysis
shRNA knockdown was evaluated by Western blot. Transduced
or control cells were counted, and the same numbers of cells
were lysed directly in sample buffer. Proteins then were
separated in 12.5% (w/v) SDS-PAGE and subsequently trans-
ferred onto polyvinylidene difluoride membrane (PVDF). Anti-
bodies to c-Jun, glutamine synthetase, glucocorticoid receptor
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(BD Biosciences Pharmingen, www.bdbiosciences.com), phos-
phorylated P-c-Jun (Ser 63) (Cell Signaling Technology), P-JNK
(Upstate Biotechnology, Inc.), and cyclin D1 and Sam 68 (Santa
Cruz Biotechnology, Santa Cruz, CA, USA, www.scbt.com) were
used. Secondary antibodies were sheep or donkey anti-mouse or
anti-rabbit, respectively, IgG conjugated with horseradish
peroxidase (GE Healthcare UK, Ltd., Amersham Biosciences UK,
Ltd., www.gehealthcare.com/lifesciences). Chemiluminescence
was determined using SupersignalR Westfemto Maximum
Sensitivity Substrate (Termo Scientific, www.piercenet.com).
For GR immunofluorescence, cells were fixed with 4%
paraformaldehyde and permeabilized with 0.1% Triton X-100.
Secondary antibody a-mouse IgG Alexa 488 was used (Invitro-
gen, www.invitrogen.com). The nuclei were counterstained with
Hoechst 33258 (Sigma).
Proliferation assays
Methylthiazolyldiphenyl-tetrazolium bromide (MTT, Sigma) cell
proliferation assays were carried out as described elsewhere.(20)
Briefly, cells were seeded at low cell concentrations (500 to 1000
cells/cm2) and cultured with the corresponding medium. Cells
were first treated with 2mg/mL of MTT at 378C for 3 hours. The
dye then was extracted with isopropanol HCl 0.04 N, and the
water-insoluble formazan was solubilized for 2 hours before
measurement of absorbance (570 nm) using an Ultrospec 2000
spectrophotometer. Cells were seeded at these low concentra-
tions and then treated as mentioned earlier. When conditions
reached confluence, an MTT proliferation assay was performed.
Flow cytometry
For cell cycle analysis, hBMSCs were seeded at 1500 cells/cm2,
serum starved, and subsequently stimulated with the corre-
sponding treatment for an additional 24 hours. Cells were
trypsinized and washed twice with fluorescence-activated cell-
sorting (FACS) buffer (PBS, 1% heat-inactivated FBS, 1%
bovine serum albumin) and then incubated in FACS buffer
containing 0.1% saponin and subsequently stained with
1mg/mL propidium iodide (Sigma) for 1 hour at 48C. For
adipocyte quantification, cells were cultured for the indicated
time in the presence of adipogenic medium, and the
adipocyte number was assessed using Nile red as described
previously.(20)
Results
RNAi-mediated GR suppression substantially attenuates
hBMSC adipogenesis and osteogenesis
We first confirmed that glucocorticoid receptor (GR) was
responsive to steroid hormone in hBMSCs by incubating them
with the synthetic glucocorticoid dexamethasone (Dex). As
expected, Dex induced rapid translocation of GR into the nucleus
(Fig. 1A). To clarify the role of this active GR in hBMSC
differentiation, we used a GFP-expressing lentiviral vector
(pLVTHM) to transduce hBMSCs at various multiplicities of
infection with a stable GR-specific shRNA (GRi). This reduced GR
protein expression to less than 10% of control (Fig. 1B). Using
flow cytometry of Nile red staining and side scatter to quantify
adipogenesis,(20) we observed that cells in which the GR was
‘‘knocked down’’ (GFPþ) generated almost threefold fewer
adipocytes in adipogenic medium (AM) compared with pLV-
empty GFPþ control cells (Fig. 1C). Inhibition of GR protein
expression also blocked the synthesis of calcium matrix, as
assessed by alizarin red S staining, in the presence of osteogenic
medium (OM) (Fig. 1D and Supplemental Fig. 2A). This indicates
Fig. 1. GR-specific gene silencing impaires osteo/adipogenesis capacity of hBMSCs. (A) Internalization of the glucocorticoid receptor in response to
dexamethasone (Dex). hBMSCs were incubated in the presence of 1mMDex for 24 hours. (GR green, nuclei blue). (B) Western blot analysis of GR expression
after specific knock-down in hBMSCs transduced with pLV-GRi. Control: pLVTHM empty vector (pLV-emp). Sam68 was used as a loading control. Effects
of GR silencing on hBMSC adipogenesis (C) and osteogenesis (D). Analysis of GFP expression by flow cytometry. hBMSCs transduced with pLVTHM were
harvested, and GFP expression was analyzed by flow cytometry (white). Negative control: noninfected hBMSCs (gray). hBMSCs transduced with either the
empty or GRi-containing vector were induced to differentiate in the presence of adipogenic medium (AM) or osteogenic medium (OM). (C) Percentage of
mature adipocytes stained with Nile red was estimated by flow cytometry. Percentage of GFPþ and GFP– mature adipocytes after the induction period are
represented by bars. Results show the mean SD of triplicate samples. Significance of the difference between GFPþ and GFP– in pLV-GRi cells was
determined using Student’s t test; p< .01. (D) Osteogenic induction of transduced hBMSCs. Cells were stainedwith alizarin red S. Control: absence of OM.
Alizarin red calcium quantification is shown in Supplemental Fig. 2A.
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that GR activity in hBMSCs is necessary for both osteogenesis
and adipogenesis. To confirm that these GR-dependent effects
were a consequence of GC interaction, we demonstrated that
hBMSC differentiation in the presence of Dex to either an
osteogenic or adipogenic fate was inhibited in a dose-dependent
manner by RU-486, a GC antagonist used widely to examine GR-
mediated Dex action (Supplemental Fig. 2B).
GR signaling negatively regulates hBMSC proliferation
Although the differentiation process of hBMSCs toward the
osteoblast/adipocyte lineages appears sensitive to GC, whether
this effect can be dissociated from an effect on precursor
proliferation is unclear. To investigate the role of GC/GR signaling
on hBMSC proliferation, the ratio of GFPþ to GFP– cells was
determined after transduction of hBMSCs with the GFP-
expressing GRi or control vectors. As expected, in the presence
of Dex (1mM), empty vector–transduced hBMSCs maintained
a constant ratio of GFP expression throughout the culture period
(10 days). In contrast, the percentage of GFPþ cells increased in
the GRi-transduced cultures after reaching confluence (Fig. 2A).
To further determine the effect on proliferative capacity,
nontransduced hBMSCs (at 500 cells/cm2) were exposed to
increasing concentrations of Dex (103 to 102 mM), maintained
in culture medium for 10 days, and assayed for cell proliferation
in the presence of MTT. As shown in Fig. 2B, consistent with
the previous observations, hBMSC proliferation was inhibited in a
Dex concentration–dependent manner that peaked at 10mM.
More than 90% of the cells remained viable by trypan blue
staining, excluding any deleterious effect of the synthetic
hormone (data not shown). Thus these results confirm that GC/
GR signaling negatively regulates hBMSC proliferation in a dose-
dependent manner.
We have demonstrated previously that differentiation of
hBMSCs into adipocytes requires inhibition of cell prolifera-
tion.(20) However, the relationship between cell proliferation and
the osteogenic potential of hBMSCs was unclear. To investigate,
we observed that while expansion was negligible in AMmedium
(high Dex), hBMSCs (plated at 2 104 cells/cm2) expanded
2- and 2.5-fold in OM (low Dex) or control medium, respectively
(Fig. 2C). Cell cycle analysis by propidium iodide incorporation
and subsequent flow cytometry for DNA content confirmed
these results. As shown in Fig. 2C, AM-treated cells typically
displayed only low levels of cells in S/G2/M (10%) compared
with approximately 30% and approximately 40% cells in S/G2/M
in OM and control medium, respectively. We have shown that
several components of AM (including Dex) contribute to the
negative effect on hBMSC proliferation.(20) In contrast, Dex apart,
the other components of OM (b-glycerol phosphate and
ascorbic acid) did not affect hBMSC proliferation (data not
shown). Thus our data collectively suggest that adipogenic
and osteogenic differentiation of hBMSCs require a very
different proliferation status that can be significantly influenced
by GC/GR signaling activity.
Fig. 2. Effects of glucocorticoid receptor signaling on hBMSC proliferation. (A) hBMSC proliferation induced by specific GR inhibition in the presence of
Dex. Transduced cells were plated at 500 cell/cm2 (day 0) in the presence or absence (control) of dexamethasone (1mM) and analyzed by flow cytometry
on day 10 (left panel). One representative experiment out of three is shown (right pannel). Significance of the difference between Dex-treated and control
in pLV-GRi GFPþ cells was determined using Student’s t test (n¼ 3, p< .01). (B) hBMSC growth arrest induced by increasing concentrations of Dex.
Noninfected hBMSCs were plated at 500 cell/cm2, and cell proliferation was estimated using the MTT assay on day 10 of culture. Significance was
determined using Student’s t test for paired samples relative to the proliferation levelsmeasured on control cells (n¼ 3, p< .01). (C) Effects of AM andOM
on noninfected hBMSC cell growth. Noninfected hBMSCs were plated at 20000 cell/cm2 in the presence (AM or OM) or absence (control) of differentiation
medium. Fold increase was estimated using the trypan blue dye exclusion assay and represents the cell count in relation to the cells plated on day 0. Cell
cycle was analyzed by flow cytometry of hBMSCs stained with propidium iodide. The percentages of cells in S/G2/M are indicated. (D) hBMSCs were
assayed under the same conditions as in panel C but in the presence of 25 ng/mL of PDGF. AM¼ adipogenic medium; OM¼osteogenic medium. Results
show the mean SD of triplicate samples. Significance of the difference between control and PDGF-treated cells from panels C and D is shown in
Supplemental Fig. 3.
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PDGF antagonizes GR-mediated effects on hBMSC
proliferation and differentiation
Various growth factors, such as PDGF, have been shown to
promote proliferation of hBMSCs.(20–23) Since growth and
differentiation are tightly linked processes, we questioned
how proliferation affected the adipogenic and osteogenic
capacity of hBMSCs. As shown in Fig. 2D and Supplemental
Fig. 3, PDGF partially rescues the inhibition of proliferation that is
observed under both AM and OM conditions, as measured by
fold expansion and percentage of cells in the S/G2/M phases of
the cell cycle. To investigate further, hBMSCs were induced to
differentiate to both lineages in the presence or absence of
PDGF. PDGF produced a greater than 60% reduction in adipocyte
formation after 21 days of culture (Fig. 3A). In contrast, PDGF
increased osteoblast differentiation from hBMSCs as mineralized
extracellular matrix were observed faster and reached higher
levels on alizarin red S staining (Fig. 3A, bottom panel).
The c-Jun NH2-terminal kinase (JNK) and, consequently, the c-
Jun protein are reported targets of PDGF signaling. Thus, to
elucidate the potential mechanism by which PDGF produces
opposing effects on the adipogenic and osteogenic differentia-
tion of hBMSCs, the activation state of JNK and c-Jun in PDGF-
treated cultures was determined by immunoblot analysis. PDGF
treatment resulted in the phosphorylation of both JNK and c-Jun
(Fig. 3B). The PDGF-induced phosphorylation of c-Jun was
completely prevented by pretreatment with the JNK inhibitor
SP600125 (Fig. 3B). Furthermore, under AM conditions, SP600125
was able to rescue the PDGF-mediated reduction in the
percentage of hBMSCs that differentiated into adipocytes
(Fig. 3A, upper panel). In contrast, the osteogenic potential of
hBMSCs was reduced in the presence of SP600125, even when
PDGF was added (Fig. 3A, bottom panel). Taken together, these
data implicate JNK/c-Jun activation in the opposing actions of
PDGF on the adipogenic and osteogenic capacity of hBMSCs.
GR and PDGF oppositely regulate c-Jun protein
expression in hBMSCs
c-Jun plays a role in many cellular processes in response to
growth factor ligands, forming Jun-Jun and Fos-Jun dimmers
and activating AP-1 sites. Curiously, among important regulatory
elements identified in the c-Jun promoter are two AP-1 sites,
which suggest that c-Jun transcription could be regulated by its
own gene product.(24,25) To further understand the role of c-Jun
in the regulation of hBMSC proliferation and differentiation, c-
Jun expression kinetics were investigated after PDGF treatment.
PDGF elicited a rapid induction of c-Jun protein expression in a
dose-dependent manner that peaked at 25 ng/mL (Fig. 4A, top
panel). At this concentration of PDGF, c-Jun was first evident at
30minutes and peaked at 24 hours (Fig. 4A, bottom panel),
suggesting that in hBMSCs, c-Jun phosphorylation and sub-
sequent activation stimulate its own transcription.
We next determined whether AM or OM conditions affected c-
Jun expression in hBMSCs. Both media resulted in a considerable
reduction in c-Jun protein at 24 hours by Western blot (Fig. 4B).
Interestingly, a similar inhibition also was observed for cyclin D1,
a proliferation-inducing gene known to be AP-1-responsive(26)
(Supplemental Fig. 4). Analysis of individual components of the
differentiation medium showed that Dex was the major factor
that reduced c-Jun protein levels and that the higher Dex
concentration in AM versus OM was responsible for the different
c-Jun levels observed between the two treatments (Supple-
mental Fig. 5). Significantly, downregulation of c-Jun expression
by AM or OMwas reversed in the presence of PDGF (Fig. 4B). This
rescue depended on PDGF-mediated JNK signaling because
SP600125 treatment abolished the induction of c-Jun expression
(Fig. 4B).
Since Dex appeared to reduce c-Jun expression when hBMSCs
were cultured in OM or AM, we next investigated the role of GR in
c-Jun regulation by using the GRi vector. In GR knockdown
conditions, Dex did not decrease cyclin D1 protein expression
(Supplemental Fig. 6A), whereas c-Jun protein levels were
significantly maintained (Fig. 4C and Supplemental Fig. 6B). Thus
Fig. 3. hBMSC differentiation capacity is influenced by the growth factor
PDGF via JNK/c-JUN activation. (A) hBMSCs were induced to differentiate
with AM or OM in the presence/absence of PDGF (25 ng/mL) and the
specific JNK inhibitor SP600125 (4mM). Percentages of mature adipocytes
were determined by flow cytometry (upper panel). Results show the
mean SD of triplicate samples. Significance of the difference between
AM and AM/PDGF SP600125-treated cells was determined using
Student’s t test; p< .01, p< .05. Mineralized bone structures were
revealedwithalizarin redSstain (bottompanel). (B) PDGF inducedactivation
of JNK/c-Jun in hBMSCs. Cells were stimulated with PDGF (25 ng/mL), and
JNK and c-Jun phosphorylation was determined by immunoblot analysis
using phosphospecific JNK and c-Jun antibodies. hBMSCs were pretreated
for 6 hours with the inhibitor of JNK SP600125 (4mM) or with the vehicle
control,whichsignificantlypreventedthespecificphosphorylationofc-Jun.
Sam68 was used as a loading control.
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these data suggest that both activated GR and PDGF could
modify hBMSC differentiation through their effects on c-Jun
expression and subsequent cellular proliferation.
Modulation of c-Jun expression regulates hBMSC
proliferation and differentiation
To further explore the role of c-Jun in hBMSC differentiation, we
used our GFP-expressing lentiviral vectors to transduce
approximately 50% of cultures of hBMSCs with either c-Jun
cDNA (pWPI-c-Jun) or c-Jun-specific shRNA (pLV-c-Juni) or with
empty-vector controls (Fig. 5A). The pWPI-c-Jun vector increased
c-Jun protein more than 4-fold, whereas pLV-c-Juni reduced c-
Jun protein to less than 5% of control (Fig. 5A and Supplemental
Fig. 7). Since adipogenic and osteogenic potential of hBMSCs is
related to cell cycle progression, we first determined whether c-
Jun expression levels had any effect on hBMSC proliferation by
analysis of the GFPþ to GFP– ratio in hBMSCs transduced (50%)
with the empty, c-Jun cDNA, or c-Juni viral vectors. As expected,
hBMSCs infected with both empty vectors maintained a constant
ratio of GFP expression throughout the culture period (Fig. 5B). In
contrast, c-Jun overexpression produced a continuous, albeit
small, increase in transduced cells from week 6 of the culture,
whereas cells transduced with shRNA c-Juni decreased in
number rapidly after week 2 to reach less than 10% of the culture
at week 7 (Fig. 5B). Analysis of spontaneous cell death using
Anexin-V revealed no differences in basal apoptotic rates
between GFPþ and GFP– cells (data not shown). Collectively,
these data suggest that regulation of c-Jun expression is critically
important for hBMSC proliferation.
We next tested hBMSC differentiation in AM or OM conditions
after modulating c-Jun levels with vectors carrying either c-Jun
cDNA or c-Jun-specific shRNA. In AM, pWPI-c-Jun-transduced
cells (GFPþ), which overexpressed c-Jun, produced less than 50%
of the adipocytes generated by nontransduced cells (GFP–)
(Fig. 5C). In contrast, pLV-c-Juni-transduced cells, in which c-Jun
levels were reduced, maintained a comparable level of
adipogenesis as nontransduced control cells in the same
cultures (Fig. 5D). Furthermore, knockdown of c-Jun rescued
the defect in adipocyte generation observed on culture with
PDGF to almost normal levels (Fig. 5D). Manipulation of c-Jun had
an opposite effect on the osteogenic differentiation of hBMSCs.
c-Jun overexpression resulted in areas of mineralized extra-
cellular matrix appearing more quickly and achieving higher
levels than control cultures (Fig. 5C, bottom panel). Conversely,
the reduction of c-Jun expression produced a complete
inhibition of the synthesis of mineralized extracellular matrix
(Fig. 5D). Taken together, these data demonstrate that c-Jun
protein levels in differentiating hBMSCs are intimately linked to
both proliferation and the balance between adipogenesis and
osteogenesis.
GR and AP-1 crosstalk determine the differentiation
capacity of hBMSCs
We next checked whether c-Jun protein levels interfered with GR
activity in hBMSCs. Glutamine synthetase (GS) is a glucocorticoid-
inducible enzyme that has an essential role in the metabolism of
glutamine.(27) Using a GS-specific antibody, we showed that GRi-
expressing ‘‘knockdown’’ hBMSCs were unable to express GS
protein in the presence of Dex (Fig. 6A). To evaluate whether c-
Jun expression had any effect on GS expression, we added PDGF
in the presence of Dex. Although we observed c-Jun induction in
the presence of PDGF, GS accumulation was largely unchanged
at 24 and 48 hours, only showing a significant decrease at
72 hours (Fig. 6B, upper panel). However, this PDGF-induced
inhibition of GS levels was not dependant on c-Jun, because
overexpression of c-Jun in hBMSCs (via pWPI-c-Jun) did not affect
GS accumulation (Fig. 6B, bottom panel). This suggests that PDGF
uses a c-Jun-independent pathway to interfere with GR activity.
Fig. 4. Glucocorticoid receptor activation downregulates c-Jun protein
expression level and antagonizes the PDGF-induced signaling pathway.
(A) Time- and dose-dependent effects of PDGF on c-Jun protein expres-
sion level by Western blot analysis. hBMSCs were treated with the
indicated concentrations of PDGF for 24 hours (upper panel) or with
either 25 ng/mL of PDGF or vehicle control (CTL) for the indicated time
(bottom panel). (B) AM- or OM-induced downregulation of c-Jun expres-
sion level that antagonizes PDGF-induced upregulation of c-Jun via the
JNK signaling pathway. hBMSCs were exposed to AM or OM in the
presence of PDGF (25 ng/mL) or vehicle control for 24 hours. c-Jun
expression level was measured by Western blot in total cell extracts
using the antibody for c-Jun. hBMSCs were pretreated for 6 hours with
the inhibitor of JNK SP600125 (4mM), which significantly inhibited PDGF-
induced c-Jun expression in the presence of AM. (C) Downregulation of c-
Jun protein expression requires GR activation by dexamethasone. c-Jun
protein levels were analyzed in Dex-treated (1mM, 24 hours) hBMSCs
transduced with either the empty or GRi-containing vector, as described
in Fig. 1. Sam68 was used as a loading control. Protein quantification is
shown is Supplemental Fig. 6B.
2120 Journal of Bone and Mineral Research CA´RCAMO-ORIVE ET AL.
Fig. 5. c-Jun expression level is involved in hBMSC proliferation and influences hBMSC differentiation capacity. (A) hBMSCs were transduced at different
MOIs with the bicistronic pWPI-c-Jun cDNA or pLV-c-Juni RNAi expression vector, and GFP expression was analyzed by flow cytometry. Western blot
analysis of c-Jun expression after specific knockdown or overexpression. Transduced cells (100% infected) were analyzed for protein expression by
Western blot using a specific c-Jun antibody. Control: hBMSCs transduced with the empty vector (pLV-emp). Sam68 was used as a loading control. Protein
quantification is shown in Supplemental Fig. 7. (B) c-Jun expression regulates hBMSC proliferation. hBMSCs showing approximately 50% infection
efficiency (with either pWPI-c-Jun or pLV-c-Juni vector) were plated at 2000 cells/cm2, analyzed for GFP expression weekly, and replated at the same cell
concentration until the end of the experiment. Control: cells transduced with the specific empty vector (pWPI or pLVTHM empty vector). Results show the
mean SD of triplicate samples. pWPI-c-Jun and pLV-c-Juni were significantly different from the empty vector at all indicated time points. p< .01,
p< .05. (C) c-Jun overexpression inhibits adipogenic capacity of hBMSCs. Percentage of mature adipocytes from GFP– and GFPþ cells (cells transduced
with the empty and c-Jun-cDNA expressing vectors, respectively) after the induction period are represented. c-Jun overexpression stimulates the
osteogenic capacity of hBMSCs. Formation of mineralized extracellular matrix in hBMSCs transduced with either the empty vector (pWPI-empty) or the
vector expressing c-Jun cDNA (pWPI-c-Jun), visualized by alizarin red S staining, is shown (lower panel). Significance of the difference between GFPþ and
GFP– in pWPI-c-Jun cells was determined using Student’s t test; p< .05. (D) c-Jun knockdown rescues adipogenesis from the inhibition caused by PDGF.
hBMSCs transduced with either the empty (pLV-emp) or c-Juni-expressing vector (pLV-c-Juni) were induced to differentiate to adipogenic lineages in the
presence or absence of PDGF (25 ng/mL). c-Jun knockdown inhibits hBMSC osteogenic differentiation. hBMSCs transduced with the pLV-c-Juni vector
reduced the quantity of mineralized extracellular matrix extensively compared with control cells (pLV-empty). Results show the mean SD of triplicate
samples. Significance of the difference between pLV-empty GFPþ cells in the presence/absence of PDGF (p< .05) and in the presence or absence of c-Jun
(p< .01) was determined using Student’s t test.
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To investigate the reciprocal relationship, we evaluated the
effects of different concentrations of Dex on c-Jun and GS
expression levels in 24-hour cultures of hBMSCs. Dex produced a
concentration-dependent decrease in c-Jun that was correlated
with increased GS expression (Fig. 6C). Nonetheless, there was a
concentration window of Dex (102 to 10mM) where both GR
and c-Jun appear to be active (Fig. 6C).
Finally, we investigated whether there was an effect of
increasing concentrations of Dex (103 to 102 mM) on the
adipogenic and osteogenic differentiation capacity of hBMSCs.
Commonly used Dex concentrations (0.1 and 1mM) generated
both osteoblasts and adipocytes (Fig. 6D). Half-normal percen-
tages of adipocytes were generated at 102 mM, with almost
residual differentiation below that concentration. In contrast,
areas of mineralized extracellular matrix were observed at
concentrations as low as 102 mM (Fig. 6D). Below this
concentration, we were not able to detect any osteoblast
differentiation. Interestingly, an opposite effect was seen when
higher concentrations of Dex were used; treatment with 102 mM
Dex resulted in a decrease in areas of mineralized extracellular
matrix, whereas the adipogenic capacity of hBMSCs was
maintained (Fig. 6D). Taken together, our data demonstrate
that there is an optimal concentration of Dex where both
osteocyte and adipocyte lineages can be generated. This
coincides with GR-mediated induction of gene expression (eg,
GS synthesis) and trans-repression of AP-1 (c-Jun downregula-
tion) to levels that allow adipogenesis. Maximal GR-mediated
trans-repression by higher Dex concentrations reveals a thresh-
old of c-Jun downregulation that inhibits osteoblast generation
while adipogenic capacity is maintained.
Discussion
Normal skeletal maintenance requires a balance between
mature osteoclasts and osteoblasts that implement a bone-
remodeling process. This process is sensitive to glucocorticoid
treatment, resulting in a rapid decline in bone mass on
prolonged administration.(28) In this report we have studied
the effect of the synthetic glucocorticoid Dex on the
differentiation of human bone marrow–derived BMSCs that
represent a common precursor for both osteoblasts and
adipocytes. Indeed, these results have allowed us to propose
a new model in which crosstalk between c-Jun and the
Fig. 6. GR and c-Jun crosstalk determines the differentiation capacity of hBMSCs. (A) Western blot for glutamine synthetase (GS) on cell extracts from
hBMSCs transduced with empty-vector or pLV-GRi and cultured in the presence or absence of Dex (1mM) for 24 hours. (B) Regulation of c-Jun and GS
expression by PDGF and Dex (upper panel). hBMSCs were cultured with Dex and in the presence or absence of PDGF (25 ng/mL) for the indicated time
(upper panel). Membrane was sequentially immunoblotted with specific c-Jun and GS antibodies. GS expression analysis of c-Jun-overexpressing hBMSCs
after Dex treatment (bottom panel). Cells transduced with either the empty or c-Jun cDNA-expressing vectors were cultured in the presence of Dex (1mM)
for the indicated time, and GS expression levels were determined by Western blot analysis. Sam68 was used as a loading control. (C) hBMSCs were
incubated for 24 hours in the presence of the indicated concentrations of Dex. c-Jun and GS expression levels were determined by immunoblotting. (D)
High concentrations of Dex impair osteogenesis but maintain adipogenic capacity in hBMSCs. Cells were induced to differentiate to adipocytes (above) or
osteoblasts (below) for the indicated time in the presence of increasing concentrations of Dex. Percentages of mature adipocytes after the induction period
are represented by bars. Results show the mean SD of triplicate samples. There is a significant difference between Dex concentrations in adipocyte
induction, as tested by ANOVA (p< .001). Tukey’s HSD post hoc analysis of these data yielded two homogeneous subsets, significantly different from each
other at p< .05. The first subset includes concentrations ranging from 104 to 103mM. The second subset includes concentrations above 103mM, which
induce higher percentages of adipocytes. So we conclude that treatment with Dex at 102 mM and above significantly enhances adipogenesis. Formation
of mineralized extracellular matrix was visualized by alizarin red staining.
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glucocorticoid receptor (GR) regulates the osteogenic and
adipogenic potential of hBMSCs (Supplemental Fig. 8).
Glucocorticoid signaling plays a central role in regulating
hBMSC activity. Indeed, inhibition of GR expression using an
shRNA demonstrates a necessary role for GC-GR interactions for
both osteogenesis and adipogenesis. In addition, increasing
concentrations of Dex reduce hBMSC proliferation in a dose-
dependent manner, an effect reversible by knockdown of GR
levels. This notwithstanding, our data also demonstrate that
osteogenesis and adipogenesis are differentially affected by GR
signaling. Differentiation toward the adipogenic lineage, which
requires the total absence of cell expansion, is possible at
relatively high concentrations of Dex. In contrast, lower Dex
concentrations are optimal for osteogenesis because differentia-
tion to this fate is accompanied by hBMSC proliferation. This is
consistent with the fact that adipogenic culture conditions (1 mM
Dex) produce a profound block at the G0/G1 phase of the cell
cycle compared with the almost normal hBMSC proliferation in
osteogenic medium (0.1 mM Dex). Thus GR-regulated prolifera-
tion fundamentally affects hBMSC differentiation (Supplemental
Fig. 8). In this context, previous models of bone cell differentia-
tion invariably describe a phase of proliferation (followed by
extracellular matrix maturation and mineralization).(29) Thus
proliferation may be required for the adoption of a certain gene
expression program that subsequently supports the progressive
acquisition of a fully differentiated osteogenic phenotype.
In contrast to glucocorticoid signaling, the PDGF pathway is
known to promote hBMSC proliferation. Here we show that PDGF
signaling also affects hBMSC differentiation. PDGF inhibits
adipogenesis but serves to enhance osteogenesis, an observa-
tion consistent with the recent use of PDGF as a novel
therapeutic tool to improve bone regeneration in clinical
trials.(30) We demonstrate that PDGF signaling in hBMSCs
activates JNK, which, in turn, activates c-Jun, a component of
the AP-1 complex that is implicated in many cellular processes,
including proliferation, differentiation, and cellular transforma-
tion. Our data reveal that c-Jun overexpression recapitulates the
effects of PDGF, conferring a slight proliferative advantage on
hBMSCs while enhancing areas of mineralization in our
osteogenic culture system. Consistent with this, c-Jun knock-
down inhibited both hBMSC proliferation and osteogenesis. In
contrast, elevated levels of c-Jun inhibited adipogenesis,
whereas c-Jun knockdown rescued the PDGF-mediated reduc-
tion of adipocyte generation observed in AM culture conditions.
This suggests that fine regulation of c-Jun levels, which also may
include positive reinforcement of its own expression, is a critical
parameter that controls lineage decisions between adipogenic
and osteogenic fates (Supplemental Fig. 8). As we show here, c-
Jun is known to upregulate expression of genes that induce
proliferation, such as cyclin D1. In this context, it is interesting to
note that c-Jun activity is increased in a variety of cancers,
including high-grade osteosarcoma, where it seems critical for
disease progression.(31,32) c-Jun is also highly amplified and
overexpressed in human liposarcomas, leading to undifferen-
tiated aggressive tumors associated with an early stage of
adipocyte differentiation.(33) Thus c-Jun amplification may confer
an undifferentiated and more aggressive phenotype to an
already developing tumor.
Our model, shown in Supplemental Fig. 8, proposes that
crosstalk between glucocorticoid signaling through the gluco-
corticoid receptor and growth factor signaling (eg, PDGF) via the
JNK/c-Jun pathway collaborate to dictate the differentiation
potential of hBMSCs. Glucocorticoid administration to hBMSCs
decreases c-Jun expression in a GR-dependent manner. This may
occur by two main mechanisms: by direct protein-protein
binding or by physical interaction with other cellular factors.
Interestingly, the expression of c-Jun is rapidly and dramatically
downregulated by glucocorticoids in many cell lines,(34,35)
whereas several studies have documented interaction between
AP-1 and activated GRs within the nucleus causing mutual
repression of DNA binding.(36–38) However, although our data
from hBMSCs supports a direct role for GR in the regulation of c-
Jun, PDGF-induced c-Jun does not appear to have a direct impact
on GR signaling (as judged by GS expression levels). Instead,
PDGF downregulates GR signaling with delayed kinetics (ie,
72 hours) independent of c-Jun levels.
Importantly, our results demonstrate that c-Jun expression
and active GR signaling coexist at a range of glucocorticoid
concentrations that permits hBMSCs to differentiate toward both
the osteogenic and adipogenic lineages (Supplemental Fig. 8A).
Elevation of c-Jun levels (eg, by PDGF; Supplemental Fig. 8B) and
the consequent induction of proliferation (possibly via cyclin D1;
Supplemental Fig. 9) interfere with adipogenesis, thus favoring
osteogenesis (Supplemental Fig. 8C). Conversely, a reduction in
active c-Jun, for example, when clinically administered Dex
increases GR signaling, results in hBMSC growth arrest
(Supplemental Fig. 10) and adipocyte differentiation at the
expense of bone formation (Supplemental Fig. 8D).
Glucocorticoids are administered for a range of serious
medical conditions, often in circumstances where no alternative
therapies are available. A significant example is the use of
glucocorticoids as immunosuppressant drugs, where the main
immunosuppressive and anti-inflammatory actions of glucocor-
ticoids are mediated by repression of AP-1 in cells of the immune
system. Data presented here suggest that activation of the same
pathway in hBMSCs could explain a serious side effect of
glucocorticoid treatment, namely, bone fragility. It may prove
problematic to separate unwanted glucocorticoid-mediated
effects on AP-1 from those which generate anti-inflammatory
responses. However, our study suggests that administration of
agents such as PDGF, which increase c-Jun levels and temper GR
signaling, predominantly in hBMSCs, may reduce these harmful
side effects while maintaining efficacy in the immune system.
These data also may improve our understanding of the
mechanism of action of novel synthetic glucocorticoids that
appear to have reduced side effects in recent clinical trials.(39,40)
Indeed, an improved knowledge of the comparative effects of
glucocorticoids in cells of different organ systems should pave
the way for development of improved glucocorticoid-mediated
therapies in the very near future.
Conclusion
Glucocorticoids are used actively in the clinic as anti-inflamma-
tory agents, but serious side effects, notably osteoporosis, limit
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their utility. This study aims at dissecting the role of GCs in
mesenchymal stem cell proliferation and differentiation along
the adipocyte versus osteoblast fate. Together our results
indicate that higher concentrations of GC permit adipogenesis
but impair osteogenesis, principally by inhibiting c-Jun expres-
sion and hBMSC proliferation. Conversely, osteogenesis is
favored at concentrations of GC that support hBMSC prolifera-
tion but not adipogenic differentiation. We also demonstrate
that the growth factor PDGF can antagonize the proadipogenic
effects of GC administration by increasing c-Jun levels in a JNK-
dependent manner. Indeed, our data have allowed us to propose
a new model in which crosstalk between c-Jun and the
glucocorticoid receptor regulates the differentiation potential
of marrow hBMSCs.
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